NCT04324489View on ClinicalTrials.gov

DAS181 for Severe COVID-19: Compassionate Use

NACompletedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

March 6, 2020

Primary Completion Date

April 16, 2020

Study Completion Date

April 30, 2020

Conditions

COVID-19

Interventions

DRUG

DAS181

Patient receives nebulized DAS181 (4.5 mg BID/day, a total 9 mg/day) for 10 days.

Trial Locations (1)

Unknown

Renmin Hospital of Wuhan University, Wuhan

Sponsors

Collaborators (1)

Ansun Biopharma, Inc.

All Listed Sponsors

collaborator

Ansun Biopharma, Inc.

INDUSTRY

lead

Renmin Hospital of Wuhan University

OTHER

NCT04324489 - DAS181 for Severe COVID-19: Compassionate Use | Biotech Hunter | Biotech Hunter